GH Research (GHRS) Stock Highlights

11.39 | +5.76%

2025-05-12 04:32:10

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Its focus is on developing novel and proprietary 5-Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.

Statistics

Range Today

10.6 11.48

Volume Today 125.8K

Range 1 Year

6 20.5

Volume 1 Year 43.75M

Range 3 Year

5.05 20.5

Volume 3 Year 82.93M

Range 10 Year

5.05 30.43

Volume 10 Year 107.59M

Highlights

Market Capitalization 706.5M (small)

Floating Shares 17.28M

Current Price 11.39

Price To Earnings -14.51

Price To Book 3.31

Earnings Per Share -0.75

Payout Ratio 0%

Performance

Latest +5.76%

1 Month +8.48%

3 Months -43.05%

6 Months +39.41%

1 Year -4.61%

3 Years -23.81%

5 Years -48.23%

10 Years -48.23%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.